MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Human Vaccines & Immunotherapeutics
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

399 results · 1 filter active ·
Results by year
20112025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
399 works in the cohort · of 4,299,418page 6 of 8

Labels cover 1 of 399 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 399 of 399 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affaboutunlabeled
Economic evaluation of vaccines in Canada: A systematic review
Ayman Chit, Jason K. H. Lee, Minsup Shim, Van Hai Nguyen, Paul Grootendorst, Robert Van Exan +1 more
2016· review· en· Human Vaccines & Immunotherapeutics· Economics, Econometrics and Finance
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
Improving the safety of vaccine delivery
H. P. Evans, Alison Cooper, Huw Williams, Andrew Carson‐Stevens
2016· article· en· Human Vaccines & Immunotherapeutics· Social Sciences
machine prediction:candidate · noneconsensus · none
8
citations
fundno affunlabeled
Safety of BCG vaccination and revaccination in healthcare workers
Paola Villanueva, Nigel W. Crawford, Mariana Garcia Croda, Simone Collopy, Bruno Araújo Jardim, Tyane de Almeida Pinto Jardim +11 more
2023· article· en· Human Vaccines & Immunotherapeutics· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
8
citations
affunlabeled
Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
Laura L. Hammitt, Dean Quinn, Ewa Janczewska, Francisco J. Pasquel, Richard Tytus, K. Rajender Reddy +12 more
2023· article· en· Human Vaccines & Immunotherapeutics· Medicine
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
Hope as a predictor for COVID-19 vaccine uptake
Yael Mayer, Shir Etgar, Noga Shiffman, Yuval Bloch, Shlomo Mendlovic, Ido Lurie
2021· article· en· Human Vaccines & Immunotherapeutics· Social Sciences
machine prediction:candidate · noneconsensus · none
7
citations
affunlabeled
An adjuvant-modulated vaccine response in human whole blood
Jalil Hakimi, Ali Azizi, Salvador F. Ausar, Stephen Todryk, Nausheen Rahman, Roger H. Brookes
2017· article· en· Human Vaccines & Immunotherapeutics· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
6
citations

How this was built: Screen · Findings · About